Wealth Alliance Advisory Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Wealth Alliance Advisory Group’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,800	Closed	-$126K	–	146
2018 Q3	$126K	Buy	+21,800	New	+$123K	0.06%	137

Other funds holding TRIL

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Wealth Alliance Advisory Group's TRIL Position: Q4 2018 in Review

Wealth Alliance Advisory Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2018, closing a stake of 21,800 shares — an estimated $126K sold.

Wealth Alliance Advisory Group first reported a position in TRIL in Q3 2018 and held it in 1 quarter. The position peaked at $126K in Q3 2018. 23 funds tracked by Wall St. Rank hold TRIL as of Q4 2018.

Wealth Alliance Advisory Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2018 after selling out during the quarter.
Wealth Alliance Advisory Group sold 21,800 Trillium Therapeutics Inc. shares in Q4 2018, an estimated $126K.
Wealth Alliance Advisory Group first reported a position in Trillium Therapeutics Inc. in Q3 2018 and held it in 1 quarter.
Wealth Alliance Advisory Group's Trillium Therapeutics Inc. position peaked at $126K in Q3 2018.
23 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2018.

Based on Wealth Alliance Advisory Group's 13F filing for Q4 2018, filed 28 Jan 2019.